Cyren Ltd (CYRN) Reaches $2.45 After 3.00% Up Move; Valeant Pharmaceuticals Intl (VRX) Had 6 Bullish Analysts

November 14, 2017 - By Darrin Black

Among 27 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 6 have Buy rating, 3 Sell and 18 Hold. Therefore 22% are positive. Valeant Pharmaceuticals Intl had 144 analyst reports since July 21, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained the shares of VRX in report on Tuesday, November 7 with “Buy” rating. The firm has “Buy” rating given on Thursday, June 29 by Stifel Nicolaus. As per Wednesday, January 6, the company rating was reinitiated by Susquehanna. The firm earned “Buy” rating on Thursday, May 11 by Stifel Nicolaus. The rating was maintained by Stifel Nicolaus on Wednesday, March 16 with “Buy”. The company was downgraded on Monday, March 21 by Barclays Capital. The firm has “Hold” rating given on Tuesday, July 25 by BMO Capital Markets. On Friday, October 2 the stock rating was downgraded by Morgan Stanley to “Equal-Weight”. The firm earned “Hold” rating on Monday, August 21 by H.C. Wainwright. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) earned “Neutral” rating by Goldman Sachs on Monday, November 2. See Valeant Pharmaceuticals Intl Inc (NYSE:VRX) latest ratings:

13/11/2017 Broker: Inc. Rating: Bmo Capital New Target: $16 17
09/11/2017 Broker: BTIG Research Rating: Hold Maintain
09/11/2017 Broker: H.C. Wainwright Rating: Hold New Target: $17.0 Maintain
07/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $23.0 Maintain
07/11/2017 Broker: Mizuho Rating: Sell New Target: $7.0 Maintain
06/11/2017 Broker: Canaccord Genuity Rating: Hold New Target: $16.0 Maintain
03/11/2017 Broker: TD Securities Rating: Hold New Target: $20.0 Maintain
03/11/2017 Broker: H.C. Wainwright Rating: Hold New Target: $17.0 Maintain
01/11/2017 Broker: Mizuho Rating: Sell New Target: $7.0 Maintain
30/10/2017 Broker: BMO Capital Markets Rating: Hold New Target: $16.0 Maintain

The stock of Cyren Ltd (NASDAQ:CYRN) is a huge mover today! About 66,328 shares traded or 9.21% up from the average. Cyren Ltd (NASDAQ:CYRN) has risen 13.76% since November 14, 2016 and is uptrending. It has underperformed by 2.94% the S&P500.The move comes after 5 months positive chart setup for the $95.98M company. It was reported on Nov, 14 by Barchart.com. We have $2.52 PT which if reached, will make NASDAQ:CYRN worth $2.88M more.

Investors sentiment decreased to 1.08 in Q2 2017. Its down 0.16, from 1.24 in 2017Q1. It dropped, as 53 investors sold Valeant Pharmaceuticals Intl Inc shares while 76 reduced holdings. 49 funds opened positions while 90 raised stakes. 171.89 million shares or 1.47% more from 169.41 million shares in 2017Q1 were reported. Stephens Incorporated Ar invested 0.01% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Pub Sector Pension Investment Board holds 642,017 shares. Ameriprise Financial, Minnesota-based fund reported 36,916 shares. Bnp Paribas Arbitrage Sa holds 812,472 shares or 0.04% of its portfolio. Sigma Planning Corp invested in 0.03% or 16,414 shares. 279,861 were reported by Prudential Public Ltd. Columbus Hill Capital Mgmt Limited Partnership stated it has 968,221 shares. Korea Invest Corporation, Korea-based fund reported 20,195 shares. 100,000 were reported by Alpine Glob Mgmt Lc. Riverhead Capital Management Lc invested in 0% or 1,000 shares. Tekla Cap Mngmt Lc reported 430,000 shares. Coastland Capital Limited Liability Corp invested 0.75% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Franklin Resource has invested 0% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Riggs Asset Managment invested 0.03% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Janney Montgomery Scott reported 15,026 shares.

About 5.27M shares traded. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 48.51% since November 14, 2016 and is downtrending. It has underperformed by 65.21% the S&P500.

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has market cap of $5.02 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It has a 3.7 P/E ratio. It operates through two divisions: Developed markets and Emerging markets.

CYREN Ltd. is engaged in developing and marketing information security solutions for protecting Web, e-mail and mobile transactions. The company has market cap of $95.98 million. The Firm is a Security-as-a-Service well-known provider of integrated cloud security technology solutions that mitigate cyber threats, malware attacks, information leaks, legal liability and productivity loss through the application of cyber intelligence. It currently has negative earnings. It delivers security services to a range of clients and original equipment manufacturer, and service well-known provider distribution partners, including network and security vendors offering content security gateways, unified threat management solutions and antivirus solutions, and to service providers, such as Software-as-a-Service vendors, Web hosting providers and Internet service providers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com